Financial and Strategic Analysis of Ili Chuanning Biotechnology Co., Ltd. Using the Harvard Analytical Framework
DOI:
https://doi.org/10.71204/dtz0ga10Keywords:
Chuanning Biotechnology, Financial Analysis, Harvard Analysis Framework, Synthetic Biology, Transformation StrategyAbstract
This study takes Ili Chuanning Biotechnology Co., Ltd. as the research object. Based on its financial reports from 2023 to the first half of 2025 and related public information, a comprehensive analysis is conducted using the Harvard Analytical Framework from four dimensions: strategy, accounting, finance, and prospects. The research indicates that the company maintains a leading position in the antibiotic intermediate sector by leveraging Xinjiang's resource cost advantages and large-scale fermentation capacity, achieving steady growth in operating revenue and net profit in 2023–2024. However, performance experienced a phased decline in the first half of 2025, influenced by factors such as price fluctuations of traditional products, a drop in capacity utilization, and slow progress in its synthetic biology new business. Financial analysis shows that the company's debt repayment capacity continues to improve and its profitability foundation remains solid, but asset operation efficiency has significantly declined, and cash flow quality is under pressure. In terms of prospects, the company is actively advancing its "biotechnology fermentation + synthetic biology" dual-engine strategy, yet faces multiple challenges including industry cyclical fluctuations, a sharp increase in R&D investment, and policy uncertainties. Finally, this paper proposes targeted recommendations focusing on stabilizing traditional business, accelerating new business development, enhancing operational efficiency, and optimizing capital structure, aiming to provide references for the company's sustainable growth and investor decision-making.
Downloads
References
Altman, E. I., & Hotchkiss, E. (2019). Corporate financial distress, restructuring, and bankruptcy: Analyzing leveraged finance (5th ed.). Wiley. DOI: https://doi.org/10.1002/9781119541929
Cameron, D. E., Bashor, C. J., & Collins, J. J. (2020). Synthetic biology: From bioprocessing to bioeconomy. Nature Reviews Microbiology, 18(6), 355–370.
Christensen, C. M., Raynor, M. E., & McDonald, R. (2018). What is disruptive innovation? Harvard Business Review, 93(12), 44–53.
Cusumano, M. A., Gawer, A., & Yoffie, D. B. (2021). The business of platforms: Strategy in the age of digital competition, innovation, and power. Harper Business.
Damodaran, A. (2020). Equity risk premiums: Determinants, estimation and implications—The 2020 edition [Working paper]. Stern School of Business, New York University. DOI: https://doi.org/10.2139/ssrn.3550293
Gompers, P. A., & Lerner, J. (2021). The venture capital revolution. Journal of Economic Perspectives, 35(2), 25–48.
Kothari, S. P., Li, X., & Short, J. E. (2022). The effect of R&D on future profitability and stock returns. Journal of Financial Economics, 143(2), 745–769.
Lee, S., & Park, Y. (2021). Cash flow patterns and corporate life cycle: Evidence from Asian biotech firms. Asia-Pacific Journal of Accounting & Economics, 28(4), 512–530.
Liu, X., & Zhang, C. (2022). Environmental policy and corporate financial performance in China. Environmental and Resource Economics, 81(1), 89–112.
Narayan, P. K., & Phan, D. H. B. (2019). A survey of biotechnology and pharmaceutical firms’ financial performance. Journal of Corporate Finance, 56, 1–18.
Palepu, K. G., Healy, P. M., & Bernard, V. L. (2023). The Harvard analytical framework: A strategic approach to financial analysis. In Business analysis and valuation (7th ed., pp. 45–68).
Penman, S. H., & Penman, N. (2020). Financial statement analysis and security valuation (6th ed.). McGraw-Hill.
Pisano, G. P. (2019). The evolution of science-based business: Innovating how we innovate. Harvard Business Review, 97(5), 88–97.
Zhang, L., & Wang, Y. (2021). Antibiotic intermediate market: Trends and competitive analysis. Journal of Pharmaceutical Innovation, 16(3), 245–259.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jiayi Yang (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited. Authors retain copyright of their work, and readers are free to copy, share, adapt, and build upon the material for any purpose, including commercial use, as long as appropriate attribution is given.
How to Cite
